of stereotactic radiotherapy in treating localized prostate cancer, reporting encouraging results in preventing tumor recurrence compared with conventional surgery, alongside fewer side effects, according to the findings presented.
Researchers at the latest meeting of the American Society for Radiation Oncology said an eight-year follow-up involving 123 patients found that 91% of those receiving radiotherapy remained free of tumor recurrence, compared with 84% of patients who underwent surgery.
Stereotactic radiotherapy uses highly precise radiation beams directed at the prostate gland, targeting cancer cells while limiting exposure to nearby healthy tissues.
The findings add to growing interest in radiotherapy as a potential alternative to surgery for selected patients with localized prostate cancer. However, treatment decisions should be based on individual patient circumstances and the available clinical evidence.
